Presentation is loading. Please wait.

Presentation is loading. Please wait.

Birgitta Maćešić, Mirica Rapić

Similar presentations


Presentation on theme: "Birgitta Maćešić, Mirica Rapić"— Presentation transcript:

1 Birgitta Maćešić, Mirica Rapić
Morbidity, mortality and utilisation of drugs for chronic obstructive airway diseases Birgitta Maćešić, Mirica Rapić

2 Introduction Chronic obstructive airway diseases (asthma and COPD)
COPD – prevalence 4% - 10% (increasing) COPD - the fifth cause of death (WHO) COPD – low quality of life COPD - absenteism and invalidity

3 Aims and purpose To investigate morbidity and mortality trends and utilisation of anti-asthmatics in Croatia, The obtained results might be useful in raising the awareness if anti-asthmatics drug’s utilisation is in accordance to evidence based knowledge and to forecast a future trends important for family doctors and decision makers

4 Method Primary Health Care (PHC) morbidity data – Croatian Health-service Yearbooks, 2006 – 2015 ICD-X – respiratory - J diagnostic codes J40 - J47 codes (asthma and COPD) – one group Mortality data – Annual Reports of Croatian Institute for Public Health Specific mortality – obstructive pulmonary diseases

5 Anti-asthmatic drugs utilisation data
Annual Reports of Croatian Agency for Medicinal Products and Medical Devices, Anatomic-therapeutic clasification (ATC) index Defenied daly doses/1000/day (DDD/TID)

6 Anti-asthmatics Respiratory – R, R03 – antiasthamtics
R03AC - Saba, Laba, R03BA – glukocorticoids, R03BB - anticholinergics (Sama, Lama), R03AK - adrenergics + corticosteroids, R03AL - adrenergics i anticholinergics, R03DA - xanthines, R03DC - Leukotriene receptor antagonists, R03DX - Other - omalizumab, roflumilast

7 Results Morbidity Drug utilisation Mortality

8 Morbidity of chronic obstructive airway diseases (J40 – J47)

9 Total drug utilisation – R03

10 Utilisation of specific groups

11 Mortality

12 Conclusions Decreased morbidity trend Increased drug utilisation
Higher increase in the groups of: anticholinergics (R03BB) by 4,14 times; glucocorticoids (R03BA) by 2,24 times; Leukotriene receptor antagonists ( R03DC) by 1,56 times Increased mortality trend

13 For communication Birgitta Maćešić, bacc. med. techn., Specijalistička ordinacija obiteljske medicine “Dr. Mirica Rapić”, Karlovac Mirica Rapić, specialist of Family Medicine, Specijalisitčka ordinacija obiteljske medicine “Dr. Mirica Rapić”, Karlovac


Download ppt "Birgitta Maćešić, Mirica Rapić"

Similar presentations


Ads by Google